Kenvue Presents New Research on TYLENOL with Naproxen at PAINWeek 2026

Meaningful OTC innovation does not necessarily require a new mol This is what OTC innovation looks like when clinical evidence drives the product strategy. Kenvue’s new data on TYLENOL® with Naproxen is interesting for more than just the pain-relief category. A fixed-dose combination of two established molecules — designed to combine fast onset with prolonged relief — has now been supported by Phase 3 evidence across different acute pain models. What I find particularly relevant from an OTC innovation perspective is the development logic behind it: existing active ingredients → complementary mechanisms → fixed-dose combination → rigorous clinical evidence → a new OTC proposition. This is an important reminder that meaningful OTC innovation does not necessarily require a new molecule. Sometimes the opportunity lies in recombining what we already know — and proving that the combination creates meaningful additional value for consumers. That is exactly the kind of development pathway worth watching. OTC innovation is increasingly becoming evidence-driven. #OTC #ConsumerHealthcare #OTCInnovation #SelfCare #PainManagement #VantageOTC #ClinicalEvidence #PharmaInnovation

https://lnkd.in/geKabCXy Twelve years of research. Eight clinical studies. One goal: expanding access to effective, non-opioid OTC pain relief. At PAINWeek 2026, we're sharing new Phase 3 clinical data that further strengthens the evidence behind TYLENOL® with Naproxen and reflects more than a decade of work to bring this innovation to patients. Innovation in pain management isn't just about what's new. It's about generating the rigorous evidence that gives healthcare professionals confidence and helps people make informed choices about their care. The findings presented this week demonstrate the powerful, long-lasting relief TYLENOL® with Naproxen can provide across two rigorous post-surgical pain models. For an OTC medicine, that's a high evidentiary bar and an important benchmark for the category. I'm especially proud that these results build on one of the most extensive clinical programs behind an OTC pain innovation in the past decade. Thank you to the scientists, clinicians, research partners, and colleagues who made this milestone possible. It's exciting to see the science continue to advance as we move closer to bringing this new option to consumers nationwide. #WeAreKenvue #TYLENOL #PainManagement #PAINWeek #Research #SelfCare

Hot Plate Analgesia Meter FM-HAM-A100 This Pain Awareness Month, Fison Instruments recognizes the preclinical research that underpins progress in pain management and analgesic drug development. The FM-HAM-A100 supports the accurate, repeatable pain threshold data that pharmacological research teams rely on. Key capabilities: ✔️ Controlled temperature range of 50°C to 55°C ✔️ Temperature display and control accuracy of 0.01°C ✔️ Timing range of 0.01 to 6000 seconds with 0.01s time error ✔️ 7-inch high-definition capacitive touchscreen with simultaneous indicator display ✔️ Displays actual temperature, set temperature, pain threshold time, and foot-lift count ✔️ Storage capacity for up to 100 data groups ✔️ Panel key, foot switch, and remote-control timing options ✔️ USB and RS232 data interfaces ✔️ Plexiglass cylinder (220mm) with 190mm hot plate diameter Purpose-built for pharmacological research, drug evaluation, and pain studies involving mice and rats — supporting the preclinical work behind advances in analgesic treatment and pain management. info@fison.com Learn more: https://lnkd.in/dg8iSgyu #Fison #HotPlateAnalgesiaMeter #PainAwarenessMonth #AnalgesiaResearch #PainThresholdTesting #PharmacologyResearch #AnimalResearch #Instrumentation

Why is levorphanol often called the "Swiss Army Knife" of opioids? 🧬 While frequently overlooked in modern pain management, levorphanol boasts a unique multimodal pharmacological profile that sets it apart from traditional \mu-opioid agonists like morphine or oxycodone. Here is a breakdown of its multi-target mechanism and distinct pharmacokinetic profile: Triple Opioid Receptor Agonist: Full agonist at \mu- (MOR), \kappa- (KOR), and \delta- (DOR) opioid receptors, providing potent analgesia across central and peripheral pathways. NMDA Receptor Antagonism: Acts as an N-methyl-D-aspartate (NMDA) receptor antagonist, reducing central sensitization, mitigating neuropathic pain, and helping slow the development of opioid tolerance. SNRI Activity: Inhibits the reuptake of both norepinephrine and serotonin, adding a descending pain-pathway modulation mechanism similar to SNRIs. Metabolism & PK Advantage: Metabolized primarily via UGT2B7 glucuronidation rather than the CYP450 enzyme system. This yields minimal CYP-mediated drug interactions, high oral bioavailability (~70%), and a long elimination half-life (t_{1/2} \approx 11\text{–}16\text{ hours}). Clinical Watch-out: Because of its long terminal half-life, levorphanol can accumulate with repeated dosing, requiring cautious titration to prevent delayed respiratory depression. Have you utilized levorphanol in refractory or complex neuropathic pain cases? Share your insights below! 👇 #Pharmacology #Levorphanol #PainManagement #ClinicalPharmacology #Pharmacy #OpioidPharmacology #MedicalEducation #PainMedicine

Evaluating trajectory data for weight regain following GLP-1 therapy discontinuation: A Bayesian meta-analysis reveals that patients regain half of their treatment-associated weight loss within approximately 7.5 months of stopping semaglutide or tirzepatide. For community and health-system pharmacists, these findings underscore the necessity of proactive patient counseling on long-term weight management, addressing therapy gaps, and exploring real-world maintenance strategies. Read More: https://hubs.li/Q04xm8j10

💊 One molecule, two mechanisms: exploring a different approach to pain management Pain is a complex experience involving multiple biological pathways. Traditional opioid analgesics primarily exert their effects through μ-opioid receptor activation, while newer approaches aim to address pain mechanisms through complementary pathways. A review published in Die Pharmazie explores the pharmacological profile of tapentadol, an analgesic characterized by its dual mechanism of action: 🔹 μ-opioid receptor agonism 🔹 Noradrenaline reuptake inhibition By combining these two mechanisms within a single molecule, tapentadol provides analgesic effects through complementary pathways and has been investigated in the management of: 🔹 Acute pain 🔹 Chronic pain 🔹 Mixed pain conditions The review discusses tapentadol’s pharmacological properties, analgesic response, safety profile, and comparisons with other opioid analgesics. 📄 Read more: https://lnkd.in/gtUm8mBR ✍️ Authors: D. Krtinic, G. N. Rankovic, A. Cvetanovic, I. Conic, M. Todorovic Mitic, M. Radic, A. Lucic Prokin, M. Cevrljakovic 🏛 Affiliations: Faculty of Medicine, University of Nis, Serbia University Clinical Center Nis, Serbia Faculty of Medicine, University of Novi Sad, Serbia University Clinical Center Vojvodina, Serbia #Pharmacology #PainManagement #DrugDiscovery

Struggling with slow recovery, stubborn inflammation, or nagging discomfort? Peptide therapy is creating new possibilities for people who want a more personalized approach to feeling and performing their best. BPC-157, TB-500, and KPV are three of the most talked-about recovery peptides—but each works differently: 🧬 BPC-157 is being studied for tissue and gastrointestinal support ⚡ TB-500 is associated with mobility and soft-tissue recovery 🌿 KPV is being explored for inflammatory balance and gut health   Which option may be right for you depends on your goals, health history, and what is actually contributing to your symptoms. Read our new comparison to learn how these peptides differ—or schedule a personalized consultation with iRevive to explore the options available to you. Educational information only. Peptide availability and eligibility vary; these peptides are not FDA-approved drugs. https://lnkd.in/dq5jFHaH #PeptideTherapy #BPC157 #RecoverySupport #FunctionalMedicine #iRevive #LWR

Ever wonder why hydrocodone response varies so dramatically between patients? It comes down to CYP2D6 activity and receptor binding profile. Hydrocodone is a semi-synthetic opioid derivative of codeine primarily used for moderate to severe pain management. Here is a breakdown of its core pharmacological profile: Mechanism of Action: Primary analgesic effect occurs via agonism at the \mu-opioid receptors (MOR) in the central nervous system. Binding inhibits presynaptic neurotransmitter release (substance P, glutamate) and hyperpolarizes postsynaptic neurons. Metabolic Pathway: Highly dependent on hepatic metabolism via two main CYP450 pathways: CYP2D6: O-demethylates hydrocodone into hydromorphone (a potent metabolite with 10–100x higher MOR affinity). CYP3A4: N-demethylates hydrocodone into norhydrocodone (an inactive/weak metabolite). Clinical Nuance: CYP2D6 poor metabolizers experience significantly reduced pain relief, while ultra-rapid metabolizers face an increased risk of opioid toxicity. Understanding these pharmacokinetic nuances is critical for personalized pain management and mitigating adverse risks. What pharmacogenomic trends are you noticing in clinical pain management practice? Let’s discuss in the comments. #Pharmacology #Hydrocodone #Pharmacokinetics #PainManagement #Pharmacy #ClinicalPharmacology #OpioidMechanisms #Medicine #Genomics #Healthcare

Non-Opioid Pain Treatment Market: Advancing Safer and Multimodal Pain Management The Global Non-Opioid Pain Treatment Market is expanding as healthcare providers and patients seek effective approaches for managing acute and chronic pain while reducing reliance on opioid medicines. Non-opioid treatments include pharmaceuticals, topical therapies, injections, neuromodulation, physical interventions, and other therapeutic approaches designed to address pain through different biological or physiological pathways. Market growth is supported by the increasing prevalence of musculoskeletal disorders, arthritis, postoperative pain, neuropathic conditions, and other pain-related disorders....

🚨 Novo Nordisk and Eli Lilly and Company published their EASD line-ups this week, 24 hours apart. Read them side by side and one thing jumps out: neither company is competing on weight loss anymore. They're competing on what kind of weight. Novo is bringing 44 abstracts to Milan. CagriSema body composition. Physical function. Bone health. Their words, not mine. Lilly is bringing eloraTZP — an amylin agonist stacked on top of tirzepatide. 17% weight loss vs 10% on tirzepatide alone. Phase 2. Amylin, not GLP-1, is the story now. 📊 And here's the number nobody is quoting. EMBRAZE, Nature Medicine, June — 102 adults, 24 weeks, tirzepatide plus a myostatin inhibitor: → Same total weight lost in both arms (~11–12 kg) → Lean mass lost: 1.6 kg with the add-on vs 3.5 kg without → Fat was 85.3% of the weight lost with it — and 69.5% without it Sit with that last one. On tirzepatide alone, roughly 3 of every 10 kilos you lose are not fat. ⚠️ CRA hat on, because ten years of monitoring trials ruined me: n=102, 24 weeks, an IV infusion every four weeks, and lean mass on a DXA scan is not the same thing as being stronger. Nobody has shown function yet. But the direction of travel is unmistakable. The industry spent five years answering "how much." It is finally being forced to answer "what." None of these molecules are in Bulgaria, not yet that is 🤷♀️. Protein and resistance training are tho. Today. Free. It's not the drug that decides what you keep. It's everything you build around it. 💪 #GLP1 #ObesityMedicine #ClinicalResearch